MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Tekmira Pharmaceuticals Corp Company Profile (NASDAQ:ABUS)

Consensus Ratings for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $12.38 (201.83% upside)

Analysts' Ratings History for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetActions
5/16/2016Chardan CapitalInitiated CoverageSell$3.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016WedbushReiterated RatingOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015RBC CapitalLower Price Target$20.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015JMP SecuritiesInitiated CoverageOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2015Maxim GroupLower Price TargetHold -> Buy$27.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015NomuraInitiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Stifel NicolausReiterated RatingPositive -> Buy$31.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Clarus SecuritiesInitiated CoverageBuy$22.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/30/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha